Source link : https://www.newshealth.biz/health-news/largest-cidp-trial-offers-promising-results-for-drug-combo/
DENVER — When combined with rHuPh20, a recombinant DNA-derived human hyaluronidase, efgartigimod, promises a new treatment option for chronic inflammatory demyelinating polyneuropathy (CIDP) , according to the results of a phase 2 multinational trial, which were reported at the 2024 annual meeting of the American Academy of Neurology. “Regardless of prior therapy for CIDP, efgartigimod […]
Author : News Health
Publish date : 2024-04-25 11:19:18
Copyright for syndicated content belongs to the linked Source.